Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
The OSE Immunotherapeutics Board of Directors Proposes the Appointment of Eric Leire, MD, as New Independent Director
OSE Immunotherapeutics, a biotech company dedicated to developing first-in-class assets in immuno-oncology and immuno-inflammation, today […]
OSE Immunotherapeutics Receives New Approval for an Early Access Program for Tedopi® in Spain in Non-Small Cell Lung Cancer
OSE Immunotherapeutics SA has announced that the Spanish Drug Agency (Agencia Espanola de Medicamentos y […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more